TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
Zhejiang clear: temporary not consider medical consumables "two votes"
 
Author:中国铭铉 企划部  Release Time:2017-4-18 10:50:11  Number Browse:473
 
Medical network on April 18 - compared to many provinces, zhejiang medicines "two votes" started very early. Even, as early as last year, the whole out of "the unity of" third-rate drug purchase new platform, is believed to have the direct reality conditions of transition to a "votes". 
 
, however, it is also the advanced molecular medicine circulation reform, the blue parker instrument, according to the province who planning commission has made clear, for medical consumables, temporary not consider implementing "two votes" at the moment. 
 
In addition, the platform of "third-rate unity" at launch, explicitly proposes that medical institutions should be in medicine at 30 days' acceptance will amount to platform, platform to transfer payment to factory. However, it is reported that 30 days have reflected the receivable most didn't actually do it. The predicament in drug purchase, or also means consumable purchase "third-rate unity", still have a long way to go. 
 
Successively put forward in many provinces and cities, or have already begun to carry out medical consumables "two votes", in the eastern developed regions, in order to "ningbo rule" stunned the industry of zhejiang province, but made it clear that no consumables "two votes", quite interesting. 
 
In addition, including Beijing, Shanghai, guangdong, the developed provinces, though not like zhejiang province said don't push, but also have not made it clear that "two votes" to push the consumable materials. 
 
Industry experts believe that this or because, the more economically developed areas, instead of resistance, the greater the reform that "boiled frog". 
 
Previous article:Chinese medicine group catalogue of drugs to be shortlisted for the negotiations Foreign drug companies are still "wait and see"
Next article:Research and development of pharmaceutical giant pipeline need: novartis govinda Pfizer rebound
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粤公网安备 44011202000029号